mercredi 7 février 2018

Onco Actu du 7 février 2018

1. Biologie

Ageing immune system may explain age-related cancer risk increase [University of Dundee]

1.4 Biologie - Technos

Sequencing Human Genome with Pocket-Sized “Nanopore” Device [NIH Director's Blog]

3.3 Prévention - Vaccins

Gov’t confirms HPV jabs for men who have sex with men [PharmaTimes]

3.4.1 Chimioprévention - aspirine

Major research project launched to crack aspirin's anti-cancer properties [Cancer Research UK]

4. Dépistage, diagnostic et pronostic

SOPHiA GENETICS Announces CE-IVD Marking of its Genomic Test for Leukemia Detection [Sophia Genetics]

4.2 Dép., diag. & prono. - Génome

IU Health Expands Precision Genomics Program for Cancer Patients [Xconomy]

5. Traitements

Positive Results in a Busy Week of Cancer Clinical Studies [OBR]

5.1 Traitements - Pré-clinique

Adding crizotinib to radiation therapy may help preserve hearing in patients with NF2 [Mass. General Hospital]

Study Identifies Potential Drug Combination for Ewing Sarcoma [NCI]

Combination treatment blocks cell growth and triggers cell death in colon cancer [Institute of Cancer Research]

5.12.2 Immunothérapies - CAR-T

CAR T-Cell Therapy Provides High Remission Rate in Paediatric and Young Adult Patients with Relapsed or Refractory B-Cell ALL [ESMO]

5.12.3 Immunothérapies-combinaisons

Bristol-Myers Squibb Sows Confusion [In the Pipeline]

5.12.5 Immunothérapies - Pharma

After FDA setback, Bellicum bolsters R&D team with ex-Genentech executive [FierceBiotech]

5.2 Pharma

Celgene Corporation Announces Positive Results from the Pivotal Phase III ‘OPTIMISMM' Study of POMALYST/IMNOVID® for the Treatment of Relapsed or Refractory Multiple Myeloma [Celgene]

Array’s encorafenib/binimetinib beats Roche’s Zelboraf in phase 3 [FierceBiotech]

Looking to grow blockbuster Pomalyst franchise, Celgene declares a win for multiple myeloma triplet in pivotal PhIII [EndPoints]

Array melanoma drugs show significant survival versus Roche drug in study [Reuters]

Encorafenib and Binimetinib Combination Treatment Demonstrates 33.6 Month Median Overall Survival (OS) in Patients with BRAF-Mutant Melanoma in Phase 3 COLUMBUS Trial [Array]

Array MEK/BRAF combo beats out Roche rival in PhIII melanoma OS showdown [EndPoints]

5.5 ASCO

Preview Of Key Abstracts From The 2018 ASCO GU Cancers Symposium [OBR]

5.5.3 ASCO (prostate)

Prostate cancer shake-up looms with new data from Pfizer, Astellas and Johnson & Johnson [FiercePharma]

5.5.4 ASCO (immunothérapies)

Roche notches fresh win amid crowd of immunotherapy cocktails [Reuters]

6. Lutte contre les cancers

Cardiff man's eight-month cancer treatment wait [BBC News]

6.10.1 Politiques (USA)

Medical and Patient Groups Warn Congress Against “Right to Try” [Xconomy]

6.6 Publications

The Journal Impact Factor: A brief history, critique, and discussion of adverse effects [arXiv]

A Festival for Persistent Identifiers [Research Data]

6.7.1 Bioinformatique

Greedy, Brittle, Opaque, and Shallow: The Downsides to Deep Learning [Wired]